In-Silico Drug Discovery

A Global Strategic Business Report

MCP35237

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

7139

EXECUTIVE POOL

5850

PRICE

811

EXPERT INPUTS

34

COMPANIES

108

DATA TABLES

172

PAGES

2

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (55)

3

CXO

5

VICE PRESIDENT

10

DIRECTOR

25

MANAGER

12

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global In-Silico Drug Discovery Market to Reach US$6.0 Billion by 2030

The global market for In-Silico Drug Discovery estimated at US$3.3 Billion in the year 2024, is expected to reach US$6.0 Billion by 2030, growing at a CAGR of 10.3% over the analysis period 2024-2030. Software as a Service, one of the segments analyzed in the report, is expected to record a 11.2% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the Consultancy as a Service segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$871.6 Million While China is Forecast to Grow at 9.9% CAGR

The In-Silico Drug Discovery market in the U.S. is estimated at US$871.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$945.7 Million by the year 2030 trailing a CAGR of 9.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.5% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

Global In-Silico Drug Discovery Market – Key Trends & Drivers Summarized

Why Is In-Silico Drug Discovery Revolutionizing Pharmaceutical R&D Pipelines?

In-silico drug discovery refers to the use of computational modeling and simulation technologies to identify, optimize, and validate drug candidates before physical experimentation. This approach is fundamentally transforming traditional drug development by enabling faster hypothesis generation, target validation, lead compound screening, and toxicity prediction—all within a virtual environment. In contrast to conventional wet-lab methods, in-silico techniques allow researchers to explore vast chemical and biological spaces quickly and cost-effectively, significantly accelerating the early stages of pharmaceutical R&D.

These platforms harness diverse tools such as molecular docking, pharmacophore modeling, quantitative structure-activity relationships (QSAR), and machine learning algorithms to simulate drug-target interactions and predict compound efficacy. With rising R&D costs and high attrition rates in clinical trials, the ability of in-silico methods to de-risk candidate selection and streamline development timelines is driving their growing adoption across biotech firms, academic institutions, and pharmaceutical companies. In-silico approaches also play a critical role in precision medicine and repurposing of existing drugs, further broadening their strategic value in a competitive innovation landscape.

What Technological Advancements Are Expanding the Scope and Accuracy of In-Silico Methods?

The in-silico drug discovery landscape is rapidly evolving with breakthroughs in computational power, algorithmic sophistication, and data integration. Advances in artificial intelligence and deep learning are enabling predictive models with higher accuracy in target identification, compound screening, and ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiling. Neural networks trained on large biochemical datasets can now infer complex structure-function relationships and suggest novel compound structures with enhanced pharmacological properties.

Cloud-based computing and high-performance computing (HPC) platforms are making it possible to perform large-scale molecular simulations, virtual screening, and multi-target optimization in real time. Integration of bioinformatics and chemoinformatics platforms is allowing researchers to analyze multi-omic data—genomics, proteomics, transcriptomics—within in-silico frameworks for more informed target discovery. Additionally, the emergence of digital twins and systems biology models is enabling researchers to simulate disease progression and drug response in silico, offering powerful tools for hypothesis testing and personalized treatment strategies.

Which Therapeutic Areas and Organizations Are Leading Adoption of In-Silico Platforms?

Adoption of in-silico drug discovery is being led by pharmaceutical companies targeting complex and high-cost therapeutic areas such as oncology, neurology, rare diseases, and infectious diseases. These domains benefit significantly from computational approaches due to the high need for precision targeting, biomarker discovery, and mechanism-of-action understanding. In oncology, for instance, in-silico tools are used to design kinase inhibitors or immunotherapies by predicting tumor-specific interactions. In neurodegenerative research, simulations help model the blood-brain barrier and identify CNS-penetrant compounds.

Academic research institutions and biotech startups are also playing a major role in advancing the use of in-silico tools, often through collaborations with software providers and data science companies. Public-private partnerships and consortiums focused on open-source molecular databases and AI-enabled platforms are supporting rapid innovation and technology democratization. Contract research organizations (CROs) are increasingly integrating in-silico services into their drug discovery offerings to meet growing client demand for time-efficient and cost-effective solutions. Furthermore, regulatory bodies are showing increasing openness to simulation-based preclinical data, further legitimizing the role of in-silico approaches in mainstream drug development.

The Growth in the In-Silico Drug Discovery Market Is Driven by Several Factors…

The growth in the in-silico drug discovery market is driven by several factors including escalating drug development costs, increased R&D complexity, and the urgent need for faster innovation cycles. As traditional laboratory and clinical workflows face growing inefficiencies, the pharmaceutical industry is turning to in-silico platforms to accelerate early-stage development, reduce dependency on animal testing, and prioritize candidates with higher success probabilities. The proliferation of biomedical big data, supported by genomic sequencing, electronic health records, and curated compound libraries, is providing the fuel for increasingly accurate and scalable computational models.

Policy and funding initiatives supporting precision medicine and AI integration in healthcare are also catalyzing market growth. The global shift toward data-driven research, especially in response to emerging diseases and public health crises, has underscored the strategic value of simulation tools in rapidly screening and repurposing therapeutics. In tandem, growing investment from venture capital, pharmaceutical alliances, and government programs is supporting platform innovation, start-up development, and talent acquisition. As demand for agile, intelligent, and predictive drug discovery frameworks rises, in-silico methods are expected to become foundational to the future of pharmaceutical innovation.

SCOPE OF STUDY

The report analyzes the In-Silico Drug Discovery market by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Software as a Service, Consultancy as a Service, Software); End-Use (Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes, Other End-Uses).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World..

SELECT PLAYERS

Abzena Ltd.; Aitia; Antiverse; Atomwise, Inc.; BenevolentAI; BioNTech SE; BioSymetrics Inc.; Certara, USA; Chemical Computing Group ULC; Clarivate; Curia Global Inc.; Dassault Systèmes SE; DenovAI; Exscientia; GenScript; Iktos; Insilico Medicine; Insitro; Isomorphic Labs; Ligand Pharmaceuticals

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy

World Market Trajectories

How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind

In-Silico Drug Discovery – Global Key Competitors Percentage Market Share in 2025 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 34 Players Worldwide in 2025 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising R&D Costs and Long Development Timelines Propel Adoption of In-Silico Drug Discovery for Faster, Cost-Efficient Candidate Screening

Advancements in AI, Machine Learning, and Deep Learning Algorithms Enhance Predictive Accuracy of Molecular Modeling and Docking

Integration of High-Throughput Virtual Screening (HTVS) Accelerates Identification of Promising Drug Candidates at Scale

Growth in Cloud Computing and GPU Acceleration Supports Real-Time Simulation and Complex In-Silico Workflows

Pharmaceutical Shift Toward Precision and Personalized Medicine Strengthens Business Case for Computationally Driven Drug Design

Expansion of Multi-Omics Data Repositories Throws the Spotlight on Data-Driven Insights for Target Validation and Biomarker Discovery

Adoption of Digital Twins and Virtual Human Models Enhances Simulation of Drug Efficacy, Toxicity, and Metabolism

Increasing Use of In-Silico Tools in Rare Disease and Orphan Drug Development Creates Opportunities in Niche Therapeutic Areas

Regulatory Acceptance of In-Silico Evidence for IND and NDA Filings Supports Broader Adoption in Preclinical Research

Integration With Laboratory Information Management Systems (LIMS) and ELNs Enables Seamless End-to-End Drug Discovery Pipelines

Rising Use of Quantum Computing in Early-Stage Drug Discovery Unlocks Potential for Ultra-Fast Molecular Property Predictions

4. GLOBAL MARKET PERSPECTIVE

World In-Silico Drug Discovery Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

World Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for In-Silico Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for In-Silico Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Software as a Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Software as a Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Software as a Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Consultancy as a Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Consultancy as a Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Consultancy as a Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Pharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES

In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030

USA Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030

Canada Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

JAPAN

In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030

Japan Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

CHINA

In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)

China Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030

China Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

EUROPE

In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Europe Historic Review for In-Silico Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for In-Silico Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

FRANCE

In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)

France Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030

France Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

GERMANY

In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030

Germany Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030

Italy Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

UNITED KINGDOM

In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030

UK Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

ASIA-PACIFIC

In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

REST OF WORLD

Rest of World Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of World Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of World 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030

Rest of World Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of World Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of World 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *
NFC Life Science Co., Ltd.	%
Photocure ASA	%

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll